Sippican Capital Advisors Abb Vie Inc. Transaction History

Sippican Capital Advisors

  • $130 Million
  • Q3 2024

A detailed history of Sippican Capital Advisors transactions in Abb Vie Inc. stock. As of the latest transaction made, Sippican Capital Advisors holds 14,790 shares of ABBV stock, worth $2.66 Million. This represents 2.24% of its overall portfolio holdings.

Number of Shares
14,790
Previous 15,460 4.33%
Holding current value
$2.66 Million
Previous $2.65 Million 10.15%
% of portfolio
2.24%
Previous 2.27%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024
SELL
$163.84 - $199.33 $109,772 - $133,551
-670 Reduced 4.33%
14,790 $2.92 Million
Q2 2024

Aug 06, 2024
SELL
$154.79 - $180.76 $66,869 - $78,088
-432 Reduced 2.72%
15,460 $2.65 Million
Q1 2024

May 02, 2024
SELL
$159.82 - $182.1 $127,856 - $145,680
-800 Reduced 4.79%
15,892 $2.89 Million
Q4 2023

Jan 30, 2024
BUY
$137.6 - $154.97 $48,160 - $54,239
350 Added 2.14%
16,692 $2.59 Million
Q3 2023

Oct 24, 2023
BUY
$133.59 - $154.65 $6,679 - $7,732
50 Added 0.31%
16,342 $2.44 Million
Q2 2023

Aug 15, 2023
SELL
$132.51 - $164.9 $12,720 - $15,830
-96 Reduced 0.59%
16,292 $2.2 Million
Q1 2023

Jul 14, 2023
SELL
$144.61 - $166.54 $20,968 - $24,148
-145 Reduced 0.88%
16,388 $2.61 Million
Q4 2022

Jan 26, 2023
SELL
$138.31 - $165.87 $8,298 - $9,952
-60 Reduced 0.36%
16,533 $0
Q3 2022

Oct 17, 2022
SELL
$134.21 - $153.93 $4,697 - $5,387
-35 Reduced 0.21%
16,593 $2.23 Million
Q2 2022

Jul 19, 2022
SELL
$137.62 - $174.96 $469,284 - $596,613
-3,410 Reduced 17.02%
16,628 $2.55 Million
Q1 2022

Apr 20, 2022
SELL
$131.98 - $163.75 $15,177 - $18,831
-115 Reduced 0.57%
20,038 $3.25 Million
Q4 2021

Jan 19, 2022
SELL
$107.43 - $135.93 $158,351 - $200,360
-1,474 Reduced 6.82%
20,153 $2.73 Million
Q3 2021

Oct 20, 2021
BUY
$106.4 - $120.78 $1,064 - $1,207
10 Added 0.05%
21,627 $2.33 Million
Q2 2021

Jul 22, 2021
BUY
$105.21 - $117.21 $5,050 - $5,626
48 Added 0.22%
21,617 $2.44 Million
Q1 2021

Apr 15, 2021
SELL
$102.3 - $112.62 $24,858 - $27,366
-243 Reduced 1.11%
21,569 $2.33 Million
Q4 2020

Jan 21, 2021
SELL
$80.49 - $108.67 $89,021 - $120,189
-1,106 Reduced 4.83%
21,812 $2.34 Million
Q3 2020

Oct 23, 2020
BUY
$85.91 - $100.83 $1.97 Million - $2.31 Million
22,918 New
22,918 $2.01 Million
Q2 2020

Jul 15, 2020
BUY
$73.37 - $98.18 $74,543 - $99,750
1,016 Added 4.51%
23,554 $2.31 Million
Q1 2020

Apr 16, 2020
SELL
$64.5 - $97.79 $30,766 - $46,645
-477 Reduced 2.07%
22,538 $1.72 Million
Q4 2019

Jan 21, 2020
SELL
$72.13 - $90.25 $2,091 - $2,617
-29 Reduced 0.13%
23,015 $2.04 Million
Q3 2019

Oct 17, 2019
BUY
$62.98 - $75.72 $86,597 - $104,115
1,375 Added 6.35%
23,044 $1.75 Million
Q2 2019

Jul 17, 2019
BUY
$65.7 - $83.98 $19,381 - $24,774
295 Added 1.38%
21,669 $1.58 Million
Q1 2019

Apr 17, 2019
BUY
$77.14 - $90.79 $30,701 - $36,134
398 Added 1.9%
21,374 $1.72 Million
Q4 2018

Jan 16, 2019
SELL
$77.85 - $96.01 $10,899 - $13,441
-140 Reduced 0.66%
20,976 $1.93 Million
Q3 2018

Nov 13, 2018
SELL
$88.91 - $98.84 $1.88 Million - $2.09 Million
-21,136 Closed
0 $0
Q2 2018

Jul 17, 2018
SELL
$89.78 - $106.23 $76,313 - $90,295
-850 Reduced 3.87%
21,136 $1.96 Million
Q1 2018

Apr 24, 2018
SELL
$92.01 - $123.21 $80,048 - $107,192
-870 Reduced 3.81%
21,986 $2.08 Million
Q4 2017

Jan 17, 2018
SELL
$89.56 - $98.21 $23,554 - $25,829
-263 Reduced 1.14%
22,856 $2.21 Million
Q3 2017

Oct 30, 2017
BUY
$69.85 - $89.22 $1.61 Million - $2.06 Million
23,119
23,119 $2.05 Million

Others Institutions Holding ABBV

# of Institutions
3,853
Shares Held
1.25B
Call Options Held
16.8M
Put Options Held
12.2M
View Full List

About AbbVie Inc.

ABBV Quotes by TradingView
  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Sippican Capital Advisors Portfolio

Follow Sippican Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sippican Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Sippican Capital Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email